title: Stroke prevention in atrial fibrillation.
abstract: Nonvalvular atrial fibrillation (AF) is an independent risk factor for stroke. The overall risk of ischemic stroke in patients experiencing AF without prior stroke averages about 5% per year, but varies depending on the presence of coexistent thromboembolic risk factors. Patients with AF with low (about 1% per year), moderate (2%-4% per year) and high (> or = 6% per year) stroke risks have been identified, but the generalizability of available risk stratification schemes to clinical practice has not been defined. Adjusted-dose warfarin (target International Normalized Ratio 2-3) is highly efficacious for prevention of stroke in patients with AF (about 60% reduction) and is relatively safe for selected patients, if carefully monitored. Aspirin has a modest effect on reducing stroke (about 20% reduction). The role of transesophageal echocardiography is routine management of AF remains unsettled. Warfarin therapy should be considered for patients with AF predicted to have a high risk of stroke and who can safely receive it. Aspirin may be indicated for patients with AF at low risk for stroke and for those who cannot safely receive adjusted-dose warfarin. For those with moderate stroke risk, individual bleeding risks during anticoagulation and patient preferences should guide antithrombotic therapy.
authors.affiliation: Department of Medicine (Neurology), University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio, TX 78284-7883, USA. Hartr@UTHSCSA.edu.
authors.forename: R G
authors.initials: RG
authors.lastname: Hart
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D019934:International Normalized Ratio; D018570:Risk Assessment; D012307:Risk Factors; D020521:Stroke / Q000209:etiology / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants